Navigation Links
Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel
Date:5/1/2012

3,545

2,054

5,013

8,366

3,892VALSTAR®

4,801

5,124

6,295

5,301

6,236FORTESTA® Gel

(969)

2,028

8,409

5,401

5,822Other Branded  Products

6,970

5,609

4,948

4,224

(265)Royalty and Other Revenue

4,221

3,751

3,829

3,813

4,319Total Endo Pharmaceuticals$375,596

$398,267

$425,511

$458,475

$363,574Qualitest$134,409

$133,047

$147,975

$151,423

$145,345American Medical Systems Men's Health

$  67,407

$  47,790

$  66,548

$  69,520

$  67,440Women's Health

45,325

46,689

38,240

39,482

33,898BPH Therapy

28,054

29,784

26,731

32,966

28,828Total AMS$140,786

$124,263

$131,519

$141,968

$130,166 HealthTronics(1)$  50,103

$  49,485

$  54,073

$  51,540

$  51,548Total Revenue$700,894

$705,062

$759,078

$803,406

$690,633(1) The services segment does not include the pro forma impact of pre-acquisition revenues from the recently acquired electronic medical records providers, Intuitive Medical Software (IMS) and meridianEMR, Inc.

 

The following table presents unaudited condensed consolidated Balance Sheet data at March 31, 2012 and Dec. 31, 2011: March 31,2012December 31,2011ASSETSCURRENT ASSETS:Cash and cash equivalents

$
248,303

$
547,620Accounts receivable, net

657,135

733,222Inventories, net

288,875

262,419Other assets

279,097

244,835Total current assets

$1,473,410

$1,788,
'/>"/>

SOURCE Endo
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related medicine technology :

1. Hospira Reports First-Quarter 2012 Results
2. Luminex Corporation Reports First Quarter 2012 Results
3. PAREXEL Reports Third Quarter Fiscal Year 2012 Financial Results
4. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
5. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
6. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
7. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
8. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
9. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
10. Cepheid Reports 2012 First Quarter Results
11. Sotera Wireless Reports FDA Clearance of ViSi Mobile™ System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/14/2014)... , July 14, 2014  GenSpera, Inc. (OTCQB: ... the treatment of cancer, announces that Kareg Corporation,s ... has issued the following research report on  the ... , Director of Research, Kareg Corporation, Initiating Coverage ... Read the full report: http://www.genspera.com/press/140711_Genspera_research_report_July2014.pdf ...
(Date:7/14/2014)... -- Medac Pharma, Inc., a privately held pharmaceutical company ... improving the effectiveness of existing medicines, announced that ... approved Rasuvo™, a subcutaneous injectable methotrexate (MTX) therapy ... polyarticular-course juvenile idiopathic arthritis (pJIA) and psoriasis. Rasuvo ... from 7.5 mg to 30 mg in 2.5 ...
(Date:7/14/2014)... Ill., July 14, 2014  Abbott (NYSE: ABT) announced today ... pharmaceuticals business to Mylan for equity ownership of a ... and Abbott,s developed markets pharmaceuticals ... represents a value of approximately $5.3 billion based on ... portion of this business generated approximately $2 billion in ...
Breaking Medicine Technology:Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 2Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 3Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 4Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 5Kareg Corporation Initiates Coverage on GenSpera with a Speculative Buy Recommendation 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 2Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 3Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 4Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 5Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 6Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 7Medac Pharma, Inc. Secures FDA Approval of Rasuvo (methotrexate) injection for Rheumatoid Arthritis, Poly-Articular-Course Juvenile Idiopathic Arthritis and Psoriasis 8Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 2Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 3Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 4Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 5Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 6Abbott to Sell its Developed Markets Branded Generics Pharmaceuticals Business to Mylan 7
... Va., Aug. 26 Radiation in any form brings risk. ... designed with safeguards in mind to minimize the risk and ... if a patient presents with a breast lump that can ... professionals must employ the most appropriate diagnostic tools that identify ...
... Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company -- JERUSALEM, August 26, 2010 ... ... (typeof(lpUnit)==,undefined,) var lpUnit=,PRN,; --> ... BitlyCB.alertResponse = function(data) { var s = ,; var first_result; // Results are keyed by longUrl, ...
Cached Medicine Technology:Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 2Media Statement: Robert Moussa, President and CEO, Dilon Diagnostics 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 2Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 3Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 4Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 5Medisafe 1 Technologies Granted Eligibility Status by the Depository Trust Company 6
(Date:7/14/2014)... brain injury specialists look back on 40 years of the ... scale in research and clinical practice, in a new Personal ... , The Personal View is published on the 40th ... Lancet article*. Since this seminal publication, the Glasgow Coma ... impairment of conscious level, the clinical hallmark of acute brain ...
(Date:7/14/2014)... 2014 A recent study published in the July ... Academy of Child and Adolescent Psychiatry confirms the ... onset criterion for diagnosis of attention-deficit/hyperactivity disorder (ADHD). , ... set at 7 in DSM-IV, has been raised to ... now set at 12, rather than an earlier age, ...
(Date:7/14/2014)... the company Tissuegnostics, the pathologist Lukas Kenner and his ... identify cancer cells in tissue sections and demonstrate the ... provides a precise picture of the disease and leads ... the results of the study, "Two independent pathologists concur ... diagnosis." , "The recently developed software offers, for the ...
(Date:7/14/2014)... and Hauppauge, NY (PRWEB) July 14, 2014 ... (RGONY), with offices in Hicksville and Hauppauge, NY, ... implant) as a long-lasting treatment for diabetic macular ... Allergan, recently obtained an additional FDA-approved indication for ... approved by the FDA in 2009 for treatment ...
(Date:7/14/2014)... There’s an old adage that says first ... Palette say the products offered in their preorder event ... can reserve The Lash Palette for $40,” said Jenelle Paris, ... , Paris explained that the first 1,000 have already been ... She went on to point out that her company is ...
Breaking Medicine News(10 mins):Health News:Scientists developed new technology for the diagnosis of cancer cells 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 2Health News:Retina Group of New York Now Offers Long-lasting Ozurdex® Treatment for Diabetic Retinopathy 3Health News:The Lash Palette Preorder Event Has Officially Begun 2
... HealthDay Reporter , FRIDAY, March 16 (HealthDay ... for kids who have a genetic predisposition to aggressive ... new research suggests. "There,s an intricate interplay between ... assistant professor of criminology at the University of Texas ...
... Musicians and their instruments often make beautiful music together, but ... of musical instruments may put their owners at risk for ... Contact dermatitis is a rash caused by an irritant or ... components of musical instruments -- such as metals, exotic woods ...
... Obesity appears to significantly increase the risk of death ... mortality even among those prescribed 18 or fewer pills ... as a marker of increased vulnerability," said Robert Langer, ... and Prevention | Nutrition, Physical Activity and Metabolism 2012 ...
... companies in overcoming common issues associated with crystal formation ... The software, which has been developed at the University ... Centre (CCDC) is called Visual HABIT. It offers a ... companies to adopt a more ,bottom up, approach to ...
... , FRIDAY, March 16 (HealthDay News) -- People with ... risk for health problems that affect the heart, an ... of psoriasis. Chronic inflammation is also a characteristic of ... said Dr. Joel Gelfand, an assistant professor of dermatology ...
... facilitate efficient production of chemicals, materials and fuels from ... Excellence (CoE) in White Biotechnology Green Chemistry Research ... or cell factories, for producing new useful compounds from ... for example, for manufacturing bioplastics or in medical applications. ...
Cached Medicine News:Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 2Health News:With Spanking, Nature and Nurture Create More Aggression, Study Suggests 3Health News:Tooting Your Horn Can Raise Risk for Skin Condition 2Health News:Obesity raises death risk tied to sleeping pills 2Health News:Obesity raises death risk tied to sleeping pills 3Health News:New technology to aid crystallization prediction 2Health News:Psoriasis Patients May Face Higher Heart Risk 2Health News:Novel plastics and textiles from waste with the use of microbes 2
This double-up gel dryer system, 100-120 V, includes 2 Model 583 gel dryers, HydroTech™ vacuum pump, and double-up rack....
... GelAir™ drying system utilizes a hot air drying ... dried on a clear cellophane support for easy ... a smooth, flat assembly surface for the drying ... frames at once. This 115 V, 60 Hz ...
... is an electrophoresis gel vacuum dryer that removes ... these gels onto cellophane or filter paper for ... which heat gels from above. The drying surface ... unit includes power cord, porous gel support, transparent ...
... The PRO6000 power supply is ... power supply product offering. It ... and genomic electrophoresis. This product ... proteomic applications such as microAmp ...
Medicine Products: